PairX Bio

What PairX Bio does

PairX Bio is a private biotechnology company headquartered in Singapore that focuses on the development of cancer immunotherapies. The firm was founded in 2020 and operates with a small team of 1-10 employees, consistent with an early-stage, R&D-oriented posture. Its publicly available web presence consists solely of a 'Launching Soon' landing page that collects visitor email addresses for future updates, with no disclosed products, pipeline candidates, scientific publications, patents, partnerships, or management team.

No core products, technology platforms, or underlying scientific approaches are disclosed in the available source material. The company has not published information about its therapeutic modalities (e.g., TCR-based therapies, antibodies, cell therapies, vaccines), target antigens, or discovery methodology, and there is no evidence of preclinical or clinical assets. As a result, the technical foundation cannot be characterized beyond the stated cancer immunotherapy focus.

Commercially, PairX Bio is pre-revenue and pre-launch. No pricing, customers, distribution channels, geographic markets served, funding rounds, or investors are disclosed. The business model is not evidenced in current sources, though the company is structured as a for-profit private entity. The 'Launching Soon' website posture and absence of any GTM, partnership, or commercial signals indicate the company is in a stealth or pre-commercial stage, with no observable revenue mechanics at present.

Name

PairX Bio

Website

https://pairxbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

PairX Bio is a private, Singapore-based biotechnology firm founded in 2020 that is developing cancer immunotherapies. The company operates with 1-10 employees and remains in a pre-launch stage, with a 'Launching Soon' corporate website and no disclosed products, pipeline, or customers.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

akta.pro secondary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Cancer immunotherapy
• Immuno-oncology therapeutics
• Biopharmaceutical development
• Oncology drug discovery
• Biotech research

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Core offering

PairX Bio is a biotechnology firm that specializes in the development of cancer immunotherapies. The company is currently in a pre-launch state, with no specific products, pipeline candidates, or services publicly disclosed on its website.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage biotech developing engineered T-cell receptor (TCR) immunotherapies for solid tumors. Directly comparable to PairX Bio as a cancer immunotherapy company focused on cell-based/engineered immune receptor approaches.
• Immunocore: Commercial-stage biotech developing TCR-based immunotherapies (ImmTAC platform) for cancer. Comparable in modality (engineered T-cell engaging therapies) and oncology focus.
• Allogene Therapeutics: Clinical-stage company developing allogeneic CAR T-cell immunotherapies for cancer. A relevant peer in the cell therapy / engineered immune receptor immunotherapy space.
• Fate Therapeutics: Clinical-stage biotech developing off-the-shelf, iPSC-derived cellular immunotherapies for cancer. Comparable as a platform-based cancer immunotherapy company.
• Iovance Biotherapeutics: Commercial-stage company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer. Comparable as a cell-based cancer immunotherapy company targeting solid tumors.
• Zymeworks: Clinical-stage biotech developing multifunctional biotherapeutics including antibody-based cancer immunotherapies. Comparable in biologic engineering and oncology focus.
• CytomX Therapeutics: Clinical-stage biotech developing masked, conditionally activated antibody-based cancer immunotherapies (Probody platform). Comparable as a platform-based cancer immunotherapy developer.

Emerging players

• Adimab: Private biotech with a yeast-based antibody discovery platform. Comparable as a platform-style cancer biologics discovery company, though Adimab operates as a discovery engine rather than a therapy developer.
• Cullinan Oncology: Biotech developing a diversified pipeline of cancer immunotherapies and targeted therapies. Comparable in oncology biologics focus and multi-asset development approach.
• Scancell Holdings: UK-based clinical-stage biotech developing cancer immunotherapies including DNA-based vaccines and antibody platforms. Comparable in cancer immunotherapy development and platform approach, with a different geographic base.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/pairxbio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PairX Bio